A phase 1, open-label, dose escalation study of the safety and preliminary efficacy of EGEN-001 in combination with carboplatin and docetaxel in women with recurrent, platinum-sensitive, epithelial ovarian cancer.

Trial Profile

A phase 1, open-label, dose escalation study of the safety and preliminary efficacy of EGEN-001 in combination with carboplatin and docetaxel in women with recurrent, platinum-sensitive, epithelial ovarian cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs GEN 1 (Primary) ; Carboplatin; Docetaxel
  • Indications Ovarian cancer
  • Focus Adverse reactions; Biomarker; Registrational
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Additional lead trial centre, actual patient no [13] identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top